Natera, Inc. (NASDAQ:NTRA) Director Sells $333,755.52 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman sold 2,614 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $127.68, for a total value of $333,755.52. Following the transaction, the director now owns 7,969 shares of the company’s stock, valued at approximately $1,017,481.92. The transaction was disclosed in a filing with the SEC, which is available at this link.

Natera Trading Down 0.1 %

NTRA opened at $127.10 on Thursday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a market cap of $15.61 billion, a P/E ratio of -40.74 and a beta of 1.53. The company has a fifty day moving average price of $113.80 and a two-hundred day moving average price of $104.89.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the prior year, the firm posted ($0.97) EPS. The firm’s quarterly revenue was up 58.1% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on NTRA shares. Canaccord Genuity Group increased their price objective on shares of Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $150.00 target price on shares of Natera in a research note on Friday, September 13th. Morgan Stanley raised their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Finally, Stephens reiterated an “overweight” rating and issued a $125.00 target price on shares of Natera in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.07.

Institutional Trading of Natera

A number of institutional investors have recently modified their holdings of NTRA. Itau Unibanco Holding S.A. bought a new position in shares of Natera in the 2nd quarter worth $28,000. Principal Securities Inc. purchased a new stake in shares of Natera in the 4th quarter worth about $32,000. Quarry LP lifted its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC lifted its position in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares during the period. Finally, YHB Investment Advisors Inc. purchased a new position in Natera during the 1st quarter valued at about $36,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.